The Role of chk2 in Response to DNA Damage in Cancer Cells

Document Type: Research Article


Department of Biology, Faculty of Science, University of Mazandaran,Babolsar, Iran


Accumulation of gene changes and chromosomal instability in response to cellular DNA damage lead to cancer. DNA damage induces cell cycle checkpoints pathways. Checkpoints regulate DNA replication and cell cycle progression, chromatin restructuring, and apoptosis. Checkpoint kinase 2 (chk2) is activated in response to DNA lesions. ATM phosphorylate chk2. The activated Chk2 kinase can phosphorylate the substrates, including the Cdc25 phosphatases, p53, PML, E2F-1, and Brca1, which has been associated with DNA repair, cell cycle arrest or induction of apoptosis. Also, Chk2 is a tumor suppressor gene that maintains genomic integrity and it has been suggested as an anticancer therapy target.


Abdel-Rahman WM. 2008. Genomic instability and carcinogenesis: an update. Curr Genomics 9: 535-541.

Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer cell 3: 421-429.

Carlessi L, Buscemi G. 2007. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6: 935-944.

Carrassa L, Broggini M. 2004. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: Differential activity in cells expressing, or not, p53. Cell Cycle 3: 1175-1179.

Castedo M, Perfettini JL. 2004. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23: 4353-4361.

Cliby WA, Roberts CJ. 1998.  Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17: 159-169.

Duong HQ, Hong YB. 2013. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med 17: 1261-1270.

Gogineni V R, Nalla A K. 2011. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett 313: 64-75.

Huang M, Miao ZH. 2008. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 7: 1440-1449.

Jobson A G, Lountos GT. 2009. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther 331: 816-826.

Karnitz L M, Flatten K S. 2005. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68: 1636-1644.

Mir Mohammadrezaei F, Mohseni kouchesfehani M,  Montazeri H, Gharghabi M, Ostad SM, Ghahremani MH. 2013. Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells. Cell Signal 25: 126-132

Pabla N, Huang S. 2008. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583.

Perona R, Moncho-Amor V. 2008. Role of CHK2 in cancer development. Clin Transl Oncol 10: 538-542.

Saldivar JC, Bene J. 2012. Characterization of the role of Fhit in suppression of DNA damage. Adv Biol Regul 53: 77-85

Stevens C, Smith L. 2003. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401-409.

Stolz A, Ertych N. 2011. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 17: 401-405.

Théard D, Coisy M. 2001. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. Biochem Biophys Res Commun 289: 1199-1204.

Yutori H, Semba S. 2008. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells. Cancer Sci 99: 524-530.

Zhang P, Wang J. 2004. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 3:3- 14.